Shares of Celcuity, Inc. (NASDAQ:CELC - Get Free Report) have earned an average rating of "Buy" from the six research firms that are presently covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $28.40.
Several analysts recently weighed in on CELC shares. Stifel Nicolaus started coverage on shares of Celcuity in a report on Tuesday, July 1st. They issued a "buy" rating and a $30.00 target price for the company. Needham & Company LLC reiterated a "buy" rating and issued a $29.00 target price on shares of Celcuity in a report on Monday, June 30th. Finally, HC Wainwright reiterated a "buy" rating and issued a $27.00 target price on shares of Celcuity in a report on Monday, May 19th.
View Our Latest Stock Report on CELC
Institutional Investors Weigh In On Celcuity
Institutional investors have recently modified their holdings of the company. Summit Investment Advisors Inc. lifted its position in shares of Celcuity by 49.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company's stock worth $45,000 after purchasing an additional 1,132 shares during the last quarter. Aquatic Capital Management LLC purchased a new stake in shares of Celcuity during the 4th quarter worth $50,000. Focus Financial Network Inc. purchased a new stake in Celcuity in the first quarter valued at $108,000. Perkins Capital Management Inc. purchased a new stake in Celcuity in the first quarter valued at $115,000. Finally, GAMMA Investing LLC lifted its position in Celcuity by 1,237.4% in the first quarter. GAMMA Investing LLC now owns 1,324 shares of the company's stock valued at $131,000 after acquiring an additional 1,225 shares during the last quarter. 63.33% of the stock is owned by hedge funds and other institutional investors.
Celcuity Price Performance
Celcuity stock traded up $0.27 during midday trading on Tuesday, reaching $13.67. The company had a trading volume of 10,820 shares, compared to its average volume of 274,931. The company has a market capitalization of $517.49 million, a P/E ratio of -4.51 and a beta of 0.45. The company has a debt-to-equity ratio of 1.14, a current ratio of 6.61 and a quick ratio of 6.61. Celcuity has a 12-month low of $7.58 and a 12-month high of $19.77. The firm's fifty day simple moving average is $11.61 and its 200-day simple moving average is $11.27.
Celcuity (NASDAQ:CELC - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, beating analysts' consensus estimates of ($0.95) by $0.09. As a group, equities analysts anticipate that Celcuity will post -2.62 EPS for the current year.
About Celcuity
(
Get Free ReportCelcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Featured Articles

Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.